Rectal Cancer Staged Before and After Neoadjuvant Chemoradiation
A 54-year-old man presents with rectal bleeding and a palpable mass 6 cm from the anal verge. Pretreatment MRI pelvis shows a circumferential tumor extending through the muscularis propria with one 9 mm mesorectal node and positive extramural venous invasion; CT chest, abdomen, and pelvis shows no distant disease. He completes long-course chemoradiation with 50.4 Gy and concurrent capecitabine.
Restaging MRI eight weeks later describes the tumor as smaller with no suspicious nodes. He undergoes low anterior resection with total mesorectal excision. Pathology shows residual adenocarcinoma, ypT2, 0 of 16 nodes positive, negative margins with a 1.2 mm circumferential resection margin, and tumor regression grade 2 (moderate response). No adjuvant chemotherapy is planned.
The abstractor is new and asks which stage fields to populate and whether the restaging MRI should replace the original clinical stage.
1. Assign the pretreatment clinical stage and the post-treatment pathologic stage, and explain which fields go where in the abstract.
Read the worked answer
Pretreatment clinical stage: cT3 cN1 cM0. Under AJCC 8th edition, T3 N1 in the rectum is stage IIIB.
Post-treatment pathologic stage: ypT2 ypN0 cM0, which is stage I. The y prefix is required because the specimen was removed after preoperative therapy, and the M category remains clinical because no pathologic assessment of distant sites occurred.
The abstract needs both. Record the pretreatment clinical TNM as the clinical stage, taken from the MRI and CT performed before any therapy. Record the ypTNM as the pathologic stage after neoadjuvant treatment. There is no conventional pTNM for this patient, because no upfront resection occurred before therapy; leaving the pTNM field blank or documenting that it is not applicable is more defensible than forcing an entry. The derived stage should be calculated from the appropriate recorded fields per your registry software and CoC guidance.
The restaging MRI does not replace the clinical stage. Clinical stage is by definition the stage before treatment, and substituting post-treatment findings would make outcomes look better than they are and break comparability across hospitals. If the restaging findings matter for documentation, put them in a text note.
2. The surgeon tells the abstractor to just use the final pathology stage and ignore the MRI findings. How should the abstractor respond, and what would be lost?
Read the worked answer
The abstractor should explain that both stages are required and serve different purposes, then document the conversation and escalate to the cancer committee liaison if needed.
Recording only ypT2N0 stage I would misrepresent the patient's actual disease burden at presentation. This patient began with node-positive, margin-threatening rectal cancer and received preoperative chemoradiation specifically because he was clinically stage III. Any analysis of stage-specific survival, treatment patterns, or quality measures would count him as an early-stage case that received unnecessary radiation, which distorts both the numerator and the denominator. It would also erase the downstaging signal that neoadjuvant therapy is meant to produce, which is exactly what registries are asked to measure.
The yp stage also carries specific information the c stage cannot: the number of nodes examined, the regression grade, and the margin status after therapy. Those are separate data items and do not substitute for clinical stage.
The practical message to the surgeon is that the registry is not second-guessing the pathology. Both are recorded because both are true, and national reporting treats them as distinct fields. If the surgeon disputes a specific clinical descriptor, the right move is a documented clarification, not deletion.
3. The tumor regression grade is 2 and the circumferential margin is 1.2 mm. What is the significance of these findings for the abstract, and do they change the stage group?
Read the worked answer
Neither changes the stage group. Stage is determined by the TNM categories: ypT2 and ypN0 with clinical M0 remains stage I regardless of regression grade or margin distance. The 1.2 mm margin is close but negative, so it does not make the resection margin positive; a positive margin would be reported as involved, not as a measured distance.
Both findings still belong in the abstract. Tumor regression grade is a required site-specific data item for rectal cancer treated with neoadjuvant therapy, and the degree of response carries prognostic information that stage alone does not capture. The circumferential resection margin is also a required item and is separately predictive of local recurrence. Recording them allows the registry to answer questions such as whether margin proximity predicts recurrence in downstaged patients, which staged data alone cannot address.
Operationally, make sure the regression grade is coded on the correct scale used by your manual, since several grading systems exist and the number 2 means different things in different schemes. Record the source document, the pathology report, and check the site-specific data item definitions rather than assuming the surgeon's verbal summary matches the report.